ghk cu los angeles GHK-Cu 7% GHK-CU ACCELERANT

[DOI] [PubMed] [Google Scholar] 32.Nobel Prize in Physiology or Medicine 1934

The Danger: If the body creates antibodies against exogenous DSIP, these antibodies might cross-react with endogenous DSIP (or DSIP-like proteins/GILZ)

Phase I Safety Profile: While topical and low-dose injectable formulations demonstrate high tolerance and minimal systemic toxicity, there is no formal Phase I safety data for chronic 85 mg/day intranasal delivery in humans

10.1021/jf2009777 J Agric Food Chem

Vitamin B12 supplementation is generally considered safe across diverse medication regimens

Journal of Medicinal Chemistry, 57 (22), 9220